Beobachtungsplan, NIS 797: A Non-Interventional Real-World Study on Dose Modifications of Enfortumab Vedotin (EV) in Combination with Pembrolizumab (P) in Previously Untreated Patients with Advanced Urothelial Carcinoma in Germany

Datei

• Artikel "Beobachtungsplan, NIS 797: A Non-Interventional Real-World Study on Dose Modifications of Enfortumab Vedotin (EV) in Combination with Pembrolizumab (P) in Previously Untreated Patients with Advanced Urothelial Carcinoma in Germany"Herunterladen(PDF, 478KB, Datei ist nicht barrierefrei)